Company Name: M6 BioHealth LTD

Establishment Time: 2025

Headquarters Location: UNIT306, 3/F, BLOCK B, CHUNG MEI CENTRE, 15 HING YIP STREET KWUN TONG, KOWLOON, HONG KONG

Business Type: A resource-integrated health management and service platform enterprise

Main Business：M6 BioHealth LTD is an emerging enterprise focusing on the sub-health field. With the mission of “integrating high-quality global resources and building a new ecosystem for sub-health intervention”, it focuses on seven core business directions: stem cells, microbiota, exosomes, skincare products, seed-based men’s health supplements, health patches, and PEMF devices. It is committed to providing scientific, diversified, and personalized sub-health improvement solutions for modern people, helping the public get rid of sub-health problems at the source and regain health and vitality.

We have a profound insight into the multi-causal and complex nature of sub-health issues, so we adhere to the core concept of “cross-field collaboration and full-chain services”. Currently, we have established in-depth strategic cooperation with 8 enterprises and institutions with core competitiveness in their respective fields, and built a sub-health service matrix covering “precision testing – scientific intervention – continuous regulation”:

• WINGOR Biotechnology: Devoted to the field of cell and gene therapy, focusing on cell innovative drugs, exosome new drugs and combined innovative therapies. It is a high-tech enterprise integrating research, development, transformation and application, and lays out the whole industrial chain industrialization services. It explores the application of cutting-edge biotechnology in in-depth sub-health regulation.
• Health Management Center of Taikang Xianlin Gulou Hospital: Introduces gut microbiota FMT-related technologies and health assessment services to solve sub-health problems from the micro-ecological perspective.
• Cooperation with Real-EVS (a professional brand for exosome products): Provides precise skin repair solutions based on exosome technology for customers.

• Jixiaojian (a brand under Meirui Health International): Advocates the concept of “smart skin care” for intelligent skincare, adheres to the principles of “high professionalism, ultra-efficiency, and no unnecessary procedures”, and combines 60% light medical aesthetics with 40% streamlined and effective skincare to bring users more cost-effective and worry-free skincare solutions.
• Kangliang Group: A group company specialized in the protection, cultivation, sales of rare seeds and health management. It explores the nutritional value of rare grains and launches targeted dietary regulation solutions to achieve sub-health improvement through “food and health preservation in integration”.
• PHROMON: Focuses on men’s sub-health issues, with its core product being a men’s vitality supplement – pumpkin seed and okra extract powder, which has obtained Australian TGA certification.
• Genfosis: Committed to developing cutting-edge DNA testing solutions and leading the development of preventive and personalized healthcare. Its “The Buddy Series Patches” are incorporated into the convenient sub-health care product system to meet the needs of daily mild intervention.
• OlyLife: Introduces intelligent human physical therapy equipment such as the P-90 Terahertz Energy Instrument, and creates convenient physical therapy solutions for home and office scenarios.

Corporate Culture：The core team of M6 BioHealth LTD brings together professionals from multiple fields such as medicine, nutrition, and health management. Adhering to the service tenets of “scientific rigor and customer-centricity”, through the systematic integration and optimization of the eight cooperative resources, it breaks the service limitations of a single field and provides one-stop sub-health management services covering “testing – assessment – intervention – follow-up” for individual users and corporate clients.

Future Outlook：M6 BioHealth LTD will continue to deepen collaboration with various partners, constantly expand the depth and breadth of sub-health services, and strive to become a core bridge connecting cutting-edge health resources with the public’s sub-health needs. It will promote the standardized and diversified development of the sub-health management industry and inject new impetus into the national health cause.